Newton, MA, United States of America

Yonqi Deng


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovator Spotlight: Yonqi Deng**

Introduction

Yonqi Deng is a prominent inventor based in Newton, MA, known for his significant contributions to pharmaceutical research and development. With a focus on creating innovative therapies, he has dedicated his career to addressing pressing medical challenges.

Latest Patents

Yonqi Deng holds one patent titled "Indazole derivatives useful as ERK inhibitors." This patent presents a compound of the Formula I or a pharmaceutically acceptable salt, solvate, or ester thereof, where specific components (R, R1, R2, R3, R4, X, m, and n) are defined. The compounds developed through this invention serve as ERK inhibitors, which are crucial in the treatment of cancer. Additionally, the patent includes pharmaceutical compositions consisting of these compounds and methods for utilizing them in cancer therapies.

Career Highlights

Deng is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company dedicated to discovering and developing innovative medicines. His work at Merck focuses on pioneering treatments that have the potential to transform patient outcomes.

Collaborations

Throughout his career, Yonqi has worked alongside notable colleagues such as Gerald Wayne Shipps, Jr. and Sie-Mun Lo. These collaborations have undoubtedly enhanced the quality and impact of his research endeavors, fostering a rich environment for innovation.

Conclusion

Yonqi Deng stands out as a dedicated inventor whose work in developing ERK inhibitors showcases his commitment to advancing medical science. His contributions at Merck Sharp & Dohme Corporation reflect a broader mission of improving health outcomes through innovative research and effective treatments. As he continues to innovate, the potential for future advancements in cancer therapy remains promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…